News Aug 28, 2016 Studies Explore Safety and Efficacy of Stem Cell Therapies Safety and efficacy of stem cell therapies were explored in two separate trials presented on Aug. 28 during ESC Congress 2016 in Rome. ... Meanwhile, a single dose of mesenchymal stem cells delivered
Read MoreCardioCell Reports Positive Results From the First Phase IIa Clinical Trial Using IV Administration of Stem Cells for Chronic Heart Failure Indications
News Aug 28, 2016 CardioCell Reports Positive Results From the First Phase IIa Clinical Trial Using IV Administration of Stem Cells for Chronic Heart Failure Indications ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 28, 2016 – Study sponsor CardioCell LLC, a
Read MoreEuropean Society of Cardiology (ESC) Congress Poster Session Reveals Results From Pre-Clinical Study Using CardioCell’s Stem Cells for Chronic Ischemic Cardiomyopathy
News Aug 28, 2016 European Society of Cardiology (ESC) Congress Poster Session Reveals Results From Pre-Clinical Study Using CardioCell’s Stem Cells for Chronic Ischemic Cardiomyopathy ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 28, 2016 – Study sponsor
Read MoreThree CardioCell-Sponsored Studies Reveal Results at the European Society of Cardiology (ESC) Congress 2016
News Aug 16, 2016 Three CardioCell-Sponsored Studies Reveal Results at the European Society of Cardiology (ESC) Congress 2016 ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 16, 2016 – CardioCell LLC, a global biotechnology company that uses allogeneic stem cells
Read MoreEuropean Society of Cardiology Selects CardioCell’s Heart Failure (HF) Study Results For ESC Congress 2016 Late-Breaking Science Session
News Jun 15, 2016 European Society of Cardiology Selects CardioCell's Heart Failure (HF) Study Results For ESC Congress 2016 Late-Breaking Science Session CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces that the
Read MoreEuropean Society of Cardiology (ESC) Selects CardioCell’s Heart Failure (HF) Study Results for ESC Congress 2016 Late-Breaking Science Session
News Jun 14, 2016 European Society of Cardiology (ESC) Selects CardioCell’s Heart Failure (HF) Study Results for ESC Congress 2016 Late-Breaking Science Session SAN DIEGO — June 14, 2016 — CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for
Read More
Circulation: Heart Failure, a Journal of the American Heart Association
News May 13, 2016 Circulation Research, a Journal of the American Heart Association A major unmet need in the field of HF drug development is the ability to identify homogeneous subsets of patients whose underlying disease is driven by a specific mechanism that can be targeted
Read MoreCardioCell in talks with investment banks for Series B; will seek global CRO by late 2016
News Apr 21, 2016 CardioCell in talks with investment banks for Series B; will seek global CRO by late 2016 CardioCell is in talks with investment banks for a Series B raise in a hopefully relatively short period of time, said CEO Sergey Sikora. The funding will go toward the
Read More